Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

Michelle Rudek-Renaut, W. D. Figg, V. Dyer, W. Dahut, M. L. Turner, S. M. Steinberg, D. J. Liewehr, D. R. Kohler, J. M. Pluda, E. Reed

Research output: Contribution to journalArticle

Abstract

Purpose: This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors. Patients and Methods: Thirty-five patients with different cancer types were enrolled. COL-3 doses were escalated from 36 mg/m2/d in successive cohorts of at least three patients. Circulating levels of MMP-2, MMP-9, vascular endothelial growth factor, and basic fibroblast growth factor were assessed during treatment. Pharmacokinetic parameters were assessed for single and multiple doses of drug. Results: Cutaneous phototoxicity was dose-limiting at 98 mg/m2/d. With the use of prophylactic sunblock, COL-3 was well tolerated at 70 mg/m2/d. The dose of 36 mg/m2/d was well tolerated without the use of sunblock. Other toxicities that did not seem to be related to dose or pharmacokinetics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neurotoxicities, fatigue, and three cases of drug-induced lupus. Disease stabilization for periods of 26+ months, 8 months, and 6 months were seen in hemangioendothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively. There was a potentially statistically significant relationship between changes in plasma MMP-2 levels and cumulative doses of drug when progressive disease patients were compared with those with stable disease or toxicity (P = .042). Conclusion: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials.

Original languageEnglish (US)
Pages (from-to)584-592
Number of pages9
JournalJournal of Clinical Oncology
Volume19
Issue number2
StatePublished - Jan 15 2001
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Matrix Metalloproteinase Inhibitors
Phototoxic Dermatitis
Neoplasms
Matrix Metalloproteinase 2
Pharmacokinetics
Sertoli-Leydig Cell Tumor
Pharmaceutical Preparations
Hemangioendothelioma
Heartburn
Maximum Tolerated Dose
Fibrosarcoma
Liver Function Tests
Matrix Metalloproteinase 9
Anorexia
Dizziness
Fibroblast Growth Factor 2
Constipation
Nausea
Vascular Endothelial Growth Factor A

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rudek-Renaut, M., Figg, W. D., Dyer, V., Dahut, W., Turner, M. L., Steinberg, S. M., ... Reed, E. (2001). Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. Journal of Clinical Oncology, 19(2), 584-592.

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. / Rudek-Renaut, Michelle; Figg, W. D.; Dyer, V.; Dahut, W.; Turner, M. L.; Steinberg, S. M.; Liewehr, D. J.; Kohler, D. R.; Pluda, J. M.; Reed, E.

In: Journal of Clinical Oncology, Vol. 19, No. 2, 15.01.2001, p. 584-592.

Research output: Contribution to journalArticle

Rudek-Renaut, M, Figg, WD, Dyer, V, Dahut, W, Turner, ML, Steinberg, SM, Liewehr, DJ, Kohler, DR, Pluda, JM & Reed, E 2001, 'Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer', Journal of Clinical Oncology, vol. 19, no. 2, pp. 584-592.
Rudek-Renaut, Michelle ; Figg, W. D. ; Dyer, V. ; Dahut, W. ; Turner, M. L. ; Steinberg, S. M. ; Liewehr, D. J. ; Kohler, D. R. ; Pluda, J. M. ; Reed, E. / Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 2. pp. 584-592.
@article{c139a48811694e54979a6cb624b5bca5,
title = "Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer",
abstract = "Purpose: This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors. Patients and Methods: Thirty-five patients with different cancer types were enrolled. COL-3 doses were escalated from 36 mg/m2/d in successive cohorts of at least three patients. Circulating levels of MMP-2, MMP-9, vascular endothelial growth factor, and basic fibroblast growth factor were assessed during treatment. Pharmacokinetic parameters were assessed for single and multiple doses of drug. Results: Cutaneous phototoxicity was dose-limiting at 98 mg/m2/d. With the use of prophylactic sunblock, COL-3 was well tolerated at 70 mg/m2/d. The dose of 36 mg/m2/d was well tolerated without the use of sunblock. Other toxicities that did not seem to be related to dose or pharmacokinetics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neurotoxicities, fatigue, and three cases of drug-induced lupus. Disease stabilization for periods of 26+ months, 8 months, and 6 months were seen in hemangioendothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively. There was a potentially statistically significant relationship between changes in plasma MMP-2 levels and cumulative doses of drug when progressive disease patients were compared with those with stable disease or toxicity (P = .042). Conclusion: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials.",
author = "Michelle Rudek-Renaut and Figg, {W. D.} and V. Dyer and W. Dahut and Turner, {M. L.} and Steinberg, {S. M.} and Liewehr, {D. J.} and Kohler, {D. R.} and Pluda, {J. M.} and E. Reed",
year = "2001",
month = "1",
day = "15",
language = "English (US)",
volume = "19",
pages = "584--592",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

AU - Rudek-Renaut, Michelle

AU - Figg, W. D.

AU - Dyer, V.

AU - Dahut, W.

AU - Turner, M. L.

AU - Steinberg, S. M.

AU - Liewehr, D. J.

AU - Kohler, D. R.

AU - Pluda, J. M.

AU - Reed, E.

PY - 2001/1/15

Y1 - 2001/1/15

N2 - Purpose: This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors. Patients and Methods: Thirty-five patients with different cancer types were enrolled. COL-3 doses were escalated from 36 mg/m2/d in successive cohorts of at least three patients. Circulating levels of MMP-2, MMP-9, vascular endothelial growth factor, and basic fibroblast growth factor were assessed during treatment. Pharmacokinetic parameters were assessed for single and multiple doses of drug. Results: Cutaneous phototoxicity was dose-limiting at 98 mg/m2/d. With the use of prophylactic sunblock, COL-3 was well tolerated at 70 mg/m2/d. The dose of 36 mg/m2/d was well tolerated without the use of sunblock. Other toxicities that did not seem to be related to dose or pharmacokinetics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neurotoxicities, fatigue, and three cases of drug-induced lupus. Disease stabilization for periods of 26+ months, 8 months, and 6 months were seen in hemangioendothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively. There was a potentially statistically significant relationship between changes in plasma MMP-2 levels and cumulative doses of drug when progressive disease patients were compared with those with stable disease or toxicity (P = .042). Conclusion: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials.

AB - Purpose: This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors. Patients and Methods: Thirty-five patients with different cancer types were enrolled. COL-3 doses were escalated from 36 mg/m2/d in successive cohorts of at least three patients. Circulating levels of MMP-2, MMP-9, vascular endothelial growth factor, and basic fibroblast growth factor were assessed during treatment. Pharmacokinetic parameters were assessed for single and multiple doses of drug. Results: Cutaneous phototoxicity was dose-limiting at 98 mg/m2/d. With the use of prophylactic sunblock, COL-3 was well tolerated at 70 mg/m2/d. The dose of 36 mg/m2/d was well tolerated without the use of sunblock. Other toxicities that did not seem to be related to dose or pharmacokinetics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neurotoxicities, fatigue, and three cases of drug-induced lupus. Disease stabilization for periods of 26+ months, 8 months, and 6 months were seen in hemangioendothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively. There was a potentially statistically significant relationship between changes in plasma MMP-2 levels and cumulative doses of drug when progressive disease patients were compared with those with stable disease or toxicity (P = .042). Conclusion: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials.

UR - http://www.scopus.com/inward/record.url?scp=0035863463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035863463&partnerID=8YFLogxK

M3 - Article

C2 - 11208854

AN - SCOPUS:0035863463

VL - 19

SP - 584

EP - 592

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -